Immuno-Oncology | Specialty

Practical Considerations in Molecular Testing in CRC

February 26th 2016

Prognostic and Predictive Markers in Colorectal Cancer

February 26th 2016

Dr. DeVita Discusses "The Death of Cancer"

February 25th 2016

In The Death of Cancer, written by Vincent T. DeVita Jr, MD, a pioneering oncologist reveals, after 50 years on the front lines of medicine, why the war on cancer is winnable, and how to get there. In an interview with OncLive hosted by Maurie Markman, MD, he speaks with DeVita on his book and his thoughts on how the field has evolved.

Immunotherapy Continues to Advance in Head and Neck Cancer

February 23rd 2016

An early-stage trial is examining the addition of nivolumab to a cetuximab regimen in head and neck squamous cell carcinoma.

Dr. Ferris on Potential of Nivolumab in Head and Neck Cancer

February 19th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab's potential as a treatment of patients with head and neck cancer, as reported in the CheckMate-141 study.

Durvalumab Granted Breakthrough Status for Bladder Cancer

February 17th 2016

The FDA has granted a breakthrough therapy designation to durvalumab as a treatment for patients with PD-L1–positive inoperable or metastatic urothelial bladder cancer following progression on prior treatment with a platinum-based regimen.

Immunotherapy Continues Rapid Advance in NSCLC

February 16th 2016

Naiyer Rizvi, MD, discusses the role of PD-L1 testing, which PD-1/PD-L1 agents have the most potential, and what is on the horizon for the use of immunotherapies in non-small cell lung cancer.

Immunology Biomarkers Taking Shape in Breast Cancer

February 15th 2016

The search for immune system biomarkers that could prove clinically useful in treating patients with breast cancer is yielding promising results, particularly in triple-negative subtypes.

Dr. Martins on Patient Selection for Nivolumab in NSCLC

February 15th 2016

Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with non–small cell lung cancer (NSCLC).

Expert Discusses Exciting Potential for Atezolizumab in Bladder Cancer

February 15th 2016

Arjun V. Balar, MD, discusses the phase II data demonstrating the efficacy of atezolizumab as a single agent, its potential as part of combination regimens, and planned clinical trials looking at immunotherapy in patients with metastatic bladder cancer.

Nivolumab, Cabozantinib Offer New Second-Line Options in RCC

February 15th 2016

Toni Choueiri, MD, discusses the CheckMate-025 and METEOR trials and the potential for nivolumab and cabozantinib in the first- and second-line settings for treating renal cell carcinoma.

PD-L1/CTLA-4 Dual Blockade Shows Promise in NSCLC

February 12th 2016

A combination checkpoint blockade with the PD-L1 inhibitor durvalumab and the anti–CTLA-4 agent tremelimumab induced a response rate of 23% in patients with advanced non–small cell lung cancer.

Dr. Sharma on PD-L1 as Biomarker for Immunotherapy in Bladder Cancer

February 12th 2016

Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.

Pembrolizumab Emerges as a Potent Treatment in NSCLC

February 11th 2016

The role of immunotherapy is emerging as an effective, and in some cases, dramatic treatment in the non-small cell lung cancer landscape.

Dr. Ramalingam on Emerging Combination Regimens in NSCLC

February 10th 2016

Suresh Ramalingam, MD, professor, Emory School of Medicine, and chief, Medical Oncology, Department of Hematology and Medical Oncology, Emory University, discusses combinations with immunotherapy agents and chemotherapy being investigated as potential treatments for patients with non–small cell lung cancer.

Immunotherapy Shows Potential in Rare Melanoma Subtype

February 9th 2016

Richard Joseph, MD, discusses the challenges of treating mucosal melanoma and what oncologists need to know prior to using immunotherapies for the treatment of both mucosal and cutaneous melanomas.

Expert Discusses Next Steps With T-VEC in Melanoma

February 8th 2016

Howard L. Kaufman, MD, discusses remaining questions regarding T-VEC, the impact of the FDA approval, and its future potential.

Nivolumab Hailed as “Game Changer” in Head and Neck Cancer

February 8th 2016

Robert Ferris, MD, PhD, discusses CheckMate-141, the biggest remaining challenges in head and neck cancer, and the potential for nivolumab as a treatment of patients with the disease.

ASCO Selects Immunotherapy as "Cancer Advance of the Year"

February 4th 2016

ASCO has named immunotherapy, targeting agents that block PD-1/PD-L1 immune checkpoint across a vast array of tumor types, as its “Cancer Advance of the Year.”

FDA Issues Complete Response Letter for Immunotherapy MCNA in Bladder Cancer

February 3rd 2016

The FDA issued a complete response letter to Telesta Therapeutics informing the company that its biologics license application for MCNA in bladder cancer would not be approved and that an additional phase III clinical trial was needed to adequately evaluate the immunotherapy.